Cancer cachexia and targeting chronic inflammation: A unified approach to cancer treatment and palliative/supportive care

Journal of Supportive Oncology

Volumn 5, Issue 4, 2007, Pages 157-162

  MacDonald, Neil ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; CAMPTOTHECIN DERIVATIVE; CYANOCOBALAMIN; CYTOCHROME P450 3A4; FIBRINOGEN; GEMCITABINE; HUMAN ALBUMIN; IBUPROFEN; ICOSANOID; ICOSAPENTAENOIC ACID; INDOMETACIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; IRINOTECAN; LEUKOTRIENE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PLATINUM COMPLEX; PROSTAGLANDIN; TAXANE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; CYTOKINE;

ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; CACHEXIA; CANCER CONTROL; CANCER GROWTH; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CHRONIC INFLAMMATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIET THERAPY; DIGESTIVE SYSTEM CANCER; HUMAN; HYPOALBUMINEMIA; LEUKOCYTE COUNT; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; NONHUMAN; NUTRITIONAL COUNSELING; PANCREAS CANCER; PROGNOSIS; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; TUMOR; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION; INFLAMMATION; METABOLISM; MORTALITY; NEOPLASM; PALLIATIVE THERAPY; PREDICTION AND FORECASTING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; CACHEXIA; CLINICAL TRIALS; CYTOKINES; HUMANS; INFLAMMATION; LEUKOTRIENES; NEOPLASMS; PALLIATIVE CARE; PREDICTIVE VALUE OF TESTS; PROSTAGLANDINS;

EID: 34250188510     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 2003;97:2919-2925. [12767108]
2. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545. [11229684]
3. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-274. [15776005]
4. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7:211-217. [15766659]
5. deVisser KA, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24-37. [16397525]
6. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-555. [12401408]
7. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 2002;13:135-141. [11900989]
8. Martin F, Santolaria F, Batista N, et al. Cytokine levels (IL-6 and IFN-γ), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 1999;11:80-86. [10080883]
9. Salgado R, Vermeulen PB, Benoy I, et al. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 1999;80:892-897. [10360671]
10. Apte RN, Krelin Y, Song X, et al. Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumor invasiveness and tumour-host interactions. Eur J Cancer 2006;42:751-759. [16530403]
11. Laviano A, Meguid MM, Rossi-Fanelli F. Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol 2003;4:686-694. [14602249]
12. Alexander JW. Immunonutrition: the role of ω-3 fatty acids. Nutrition 1998;14:627-633. [9684267]
13. Lundholm K, Daneryd P, Bosaeus I, et al. Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: effects on survival, metabolism and function. Cancer 2004;100:1967-1977. [15112279]
14. Bosaeus I, Daneryd P, Lundholm K. Dietary intake, resting energy expenditure, weight loss and survival in cancer patients. J Nutr 2002;132(11 suppl):3465S-3466S. [12421871]
15. Lundholm K, Gelin J, Hyltander A, et al. Antiinflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 1994;54:5602-5606. [7923204]
16. McMillan DC,O'Gorman P, Fearon KCH, McArdle CS. A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients. Br J Cancer 1997;76:788-790. [9310247]
17. McMillan DC, Wigmore SJ, Fearon KCH, et al. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 1999;79:495-500. [10027319]
18. Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A. Dietary long chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 2004;79:935-945. [15159222]
19. Hardman WE, Moyer MP, Cameron IL. Consumption of an omega-3 fattyacids product, INCELL AAFA, reduced side-effects of CPT-11 (irinotecan) in mice. Br J Cancer 2002;86:983-988. [11953833]
20. Hardman WE, Moyer MP, Cameron IL. Fish oil supplement enhanced CPT-11 (irinotecan) efficiency against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects. Br J Cancer 1999;81:440-448. [10507768]
21. Fearon KC, Barber MD, Moses AG, et al. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 2006;24:3401-3407. [16849754]
22. Deans C, Wigmore S. Systemic Inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care 2005;8:265-269. [15809528]
23. Falconer JS, Fearon KCH, Ross JA, et al. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 1995;75:2077-2082. [7535184]
24. Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002;4:250-255. [11937016]
25. Casamassima A, Picciariello M, Quaranta M, et al. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol 2005;173:52-55. [15592024]
26. McKeown DJ, Brown DJ, Kelly A, et al. The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small cell lung cancer. Br J Cancer 2004;91:1993-1995.[15570310]
27. Lamb GWA, McMillan DC, Ramsey S, Aitchison M. The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal cell cancer. Br J Cancer 2006;94:781-784. [16523196]
28. Crumley ABC, McMillan DC, McKernan M, et al. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer 2006;94:1568-1571. [16685271]
29. Guida M, Ravaioli A, Chiarion Sileni V, et al. Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (Italian Melanoma Inter-Group) trial. J Transl Med 2003;1:13. [14690541]
30. Pavey SJ, Hawson GAT, Marsh NA. Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell carcinoma. Blood Coagul Fibrinolysis 2001;12:51-58. [11229827]
31. Al Murri AM, Bartlett JMS, Canney PA, et al. Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 2006;94:227-230. [16404432]
32. Forrest LM, McMillam DC, McArdle CS, et al. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small cell lung cancer. Br J Cancer 2003;89:1028-1030. [12966420]
33. MacDonald N, Kasymjanova G, Dobson S, et al. Prognostic value of baseline inflammatory markers in inoperable non-small cell lung cancer (NSCLC). J Clin Oncol 2006;24(18S):17035.
34. Walsh D, Mahmoud F, Barna B. Assessment of nutritional status and prognosis in advanced cancer: interleukin-6, C-reactive protein, and the prognostic and inflammatory nutritional index. Support Care Cancer 2003;11:60-62. [12527956]
35. 12 levels associated with CRP as a predictive factor of mortality in palliative care cancer patients: a prospective study over five years. J Pain Symptom Manage 2000;20:93-103. [10989247]
36. Liebeskind JC. Pain can kill. Pain 1991;44:3-4. [2038486]
37. Page GG, Ben-Eliyahu S. Indomethacin attenuates immunosuppressive and tumor-promoting effects of surgery. J Pain 2002;3:301-308. [14622754]
38. Page GG, Blakely WP, Ben-Eliyahu S. Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats. Pain 2001;90:191-199. [11166986]
39. Smith TJ, Staats P, Deer T, et al. An implantable drug delivery system (IDDS) for refractory cancer pain improves pain control, drug related toxicity, and survival compared to comprehensive medical management (CMM). Ann Oncol 2005;16:825-833. [15817596]
40. Lillemoe KD. Palliative therapy for pancreatic cancer. Surg Oncol Clin N Am 1998;7:199-216. [9443996]
41. Andreyev HJN, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 1998;34:503-509. [9713300]
42. Ross PJ, Ashley S, O'Brien MER, et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer 2004;90:1905-1911. [15138470]
43. Davidson W, Ash S, Capra S, et al. Weight stabilization is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin Nutr 2004;23:239-247. [15030964]
44. Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: an unrecognized source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003;4:224-232. [12681266]
45. Eskandari N, Gage J, Johnson MT, et al. Cytokine-mediated modulation of cisplatin sensitivity in ovarian cancer cells. Obstet Gynecol 2001;97(suppl 1):S2.
46. Watkins LR, Maier SF. Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol Rev 2002;82:981-1011. [12270950]
47. Watkins LR, Milligan ED, Maier SF. Glial action: a driving force for pathological pain. Trends Neurosci 2001;24:450-455. [11476884]
48. Bruera F, Kuehn N, Miller MJ, et al. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991;7:6-9. [1714502]
49. Ottery FD. Rethinking nutritional support of the cancer patient: the new field of nutritional oncology. Semin Oncol 1994;21:770-778. [7992092]